Real-world evidence (RWE) increasingly informs public health and healthcare decisions
worldwide. A large database has been created (“Integrated Dataset”) that integrates primary …

Influenza vaccination can benefit most populations, including adults≥ 65 years of age, who
are at greater risk of influenza-related complications. In many countries, enhanced vaccines …

This review describes the importance of economic evaluations and real-world evidence
(RWE) for the assessment of enhanced influenza vaccines for older adults in Europe …

Individuals aged 65 years and above are at increased risk of complications and death from
influenza compared with any other age group. Enhanced vaccines, as the MF59® …

Enhanced quadrivalent influenza vaccines that include an adjuvant (aQIV) or a high dose of
antigen (QIV-HD), which stimulate a stronger immune response in older adults than the …

We estimated the effectiveness of influenza vaccines in preventing laboratory-confirmed
influenza among older adults in aged care. Electronic database searches were conducted …

Vaccine efficacy determined within the controlled environment of a clinical trial is usually
substantially greater than real-world vaccine effectiveness. Typically, this results from …

Background Age-related immunosenescence may impair the immune response to
vaccination in older adults. Adjuvanted influenza vaccines are designed to overcome …

Standard-dose quadrivalent influenza vaccines (QIV) are designed to provide protection
against all four influenza strains. Adjuvanted QIV (aQIV), indicated for individuals aged 65+ …

ABSTRACT In the United Kingdom (UK), both the MF59-adjuvanted quadrivalent influenza
vaccine (aQIV) and the high-dose QIV (QIV-HD) are preferred for persons aged 65 years …